CTOR CITIUS ONCOLOGY, INC.
Price Chart
Executive Summary
Citius Oncology filed an S-3 registration statement to register 32,931,482 shares of common stock for resale by selling stockholders, including shares underlying warrants and conversion of term loans. The filing is a contractual obligation under the May 2026 warrant inducement and loan agreements, not a new primary offering, but it enables massive potential dilution of ~35.4% of current shares outstanding. The company has only $2.6M cash (pre-financing), a going-concern warning, and is not in compliance with Nasdaq's $1.00 bid price rule, making this a distress-driven registration.
Key Financial Metrics
Actionable Insight
The massive overhang of 32.9M registrable shares (~35% dilution) will pressure CTOR shares as selling stockholders can sell at any time. The stock already trades below the $0.90 warrant exercise price, making cashless exercise likely — meaning the company may receive zero proceeds from these registrations. Monitor for stockholder approval of the warrants (required within 90 days of May 6 closing) and any strategic alternative announcement from Jefferies.
Key Facts
- S-3 registers 32,931,482 shares for resale by selling stockholders, representing ~35.4% of shares outstanding as of May 18, 2026
- Shares include 25,555,556 from Purchaser Warrants ($0.90 exercise), 894,444 Placement Agent Warrants ($1.125), 3,703,704 Conversion Shares ($1.08), and 2,777,778 Lender Warrants ($0.90)
- Company had only $2.6M cash as of March 31, 2026, with a net loss of $26.6M in the March quarter and $32.1M in H1 FY2026
- Independent auditor's report includes a going-concern explanatory paragraph
- Company received Nasdaq deficiency notice on April 22, 2026 for failing to maintain $1.00 minimum bid price
- Jefferies retained to evaluate strategic alternatives, per prior 8-K
- Company will not receive proceeds from resales; may receive up to ~$26.5M if all warrants are cash-exercised, but warrants can be exercised on a cashless basis
Financial Impact
Potential dilution of ~35.4% of current shares outstanding; maximum aggregate offering price of $27.7M based on $0.84/share reference price
Risk Factors
- Massive dilution overhang of 32.9M shares could suppress stock price for extended period
- Company may receive zero proceeds if warrants are exercised cashless, failing to address the cash runway that extends only through November 2026
- Nasdaq delisting risk if bid price remains below $1.00 beyond October 19, 2026 compliance deadline
- Going-concern risk: $2.6M cash pre-financing with $32.1M H1 net loss and $58.8M current liabilities
Market Snapshot
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3 Filing (Primary) | 0001213900-26-062864 |
| Document: ea029144701ex-fee.htm | 0001213900-26-062864 |
| Document: ea029144701ex5-1.htm | 0001213900-26-062864 |
| Document: ea029144701ex23-1.htm | 0001213900-26-062864 |
| Document: 0001213900-26-062864-index-headers.html | 0001213900-26-062864 |
| Document: 0001213900-26-062864-index.html | 0001213900-26-062864 |
| Document: 0001213900-26-062864.txt | 0001213900-26-062864 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 8, 2026
2d ago
|
EFFECT
| $0.7786 awaiting T+1 | awaiting T+1 | — | $0.6868 (+11.79%) |
|
Jun 1, 2026
8d ago
|
8-K
| $0.7830 $0.7800 | ▼ −0.38% | ▲ +0.34% | $0.6868 (−12.29%) |
|
May 29, 2026
11d ago
|
S-3
| $0.7920 $0.7830 | ▲ +1.14% | ▲ +1.28% | $0.6868 (+13.28%) |
|
May 15, 2026
25d ago
|
8-K
| $0.8290 $0.8280 | ▼ −0.12% | ▲ +0.53% | $0.6868 (−17.15%) |
|
Mar 3, 2026
14w ago
|
EFFECT
| $1.06 $1.09 | ▲ +2.83% | ▲ +2.07% | $0.6868 (−35.21%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access